MedTrace Logo

REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma

NCT07594106 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 265

Last updated 2026-05-18

No results posted yet for this study

Summary

This study is researching a new drug called REGN15505 when used alone or in combination with cemiplimab or in combination with REGN4336 in adult patients with mCRPC and ccRCC. The goal is to explore new ways to treat these cancers by helping immune cells target and destroy cancer cells.

The study will evaluate the use of REGN15505 when administered alone, in combination with cemiplimab, or in combination with REGN4336 for:

* Any side effects of study drugs
* How well the study drugs work
* How much REGN15505, cemiplimab, and REGN4336 are in the blood at different times
* If the body makes antibodies to REGN15505 or REGN4336, which may mean the study drugs will not work as well as expected
* What is the best dose of REGN15505 when administered alone and with cemiplimab and the best dose of REGN15505 and REGN4336 when used in combination

Conditions

  • Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • Clear Cell Renal Cell Carcinoma (ccRCC)

Interventions

DRUG

REGN15505

Administered per protocol

DRUG

REGN15505+Cemiplimab

Administered per protocol

DRUG

REGN15505+REGN4336

Administered per protocol

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-25
Primary Completion
2030-09-20
Completion
2030-09-20
FDA Drug
Yes

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07594106 on ClinicalTrials.gov